Echo Street Capital Management LLC Neurocrine Biosciences Inc Transaction History

Echo Street Capital Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$94.02 - $117.1 $307,257 - $382,682	3,268 New	3,268 $367,000
Q1 2023 May 12, 2023	BUY	$94.11 - $123.02 $97,592 - $127,571	1,037 Added 50.93%	3,073 $311,000
Q4 2022 Feb 13, 2023	BUY	$106.72 - $127.06 $217,281 - $258,694	2,036 New	2,036 $243,000
Q2 2022 Aug 15, 2022	SELL	$75.79 - $100.07 $419,573 - $553,987	-5,536 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$72.45 - $94.81 $200,179 - $261,960	-2,763 Reduced 33.29%	5,536 $519,000
Q4 2021 Feb 14, 2022	BUY	$79.65 - $106.22 $661,015 - $881,519	8,299 New	8,299 $707,000
Q3 2021 Nov 15, 2021	SELL	$86.18 - $99.03 $751,834 - $863,937	-8,724 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$89.43 - $102.27 $780,187 - $892,203	8,724 New	8,724 $849,000

625

94.2M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Echo Street Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Echo Street Capital Management LLC with notifications on news.